Foundation Formed to Improve Data Quality in Clinical Trials
The Foundation for Improving Data Quality (FIDQ) recently held its first meeting in Washington, DC, to outline future efforts to refine methodologies that increase the precision of subjective endpoints used in clinical trials.
FOUNDATION FORMED TO ESTABLISH SUPERIOR METHODOLOGIES
FOR IMPROVING DATA QUALITY IN CLINICAL TRIALS
Leading CNS experts gather to improve ratings precision and reduce error variance
Southeastern, PA – August 25, 2008. The Foundation for Improving Data Quality (FIDQ) recently held its first meeting in Washington, DC, to outline future efforts to refine methodologies that increase the precision of subjective endpoints used in clinical trials. FIDQ’s mission is to generate evidence through objective, non-partisan, applied research for the purpose of improving the validity, accuracy and reliability of the measurement of subjective clinical outcomes in psychopharmacology and other disease areas. The Foundation’s ultimate goal is to lead to stronger success rates of those clinical trials that rely on subjective assessments as pivotal endpoints.
The FIDQ is governed by a Council of leading central nervous system (CNS) research experts who have been selected for their specific areas of expertise in psychiatry and neurology. Serving as Chairman is Amir Kalali, MD, Vice President, Medical and Scientific Services, Global Therapeutic Group Leader CNS, Quintiles Transnational Corporation. According to Dr. Kalali, “There is a great need for taking clinical trial methodology in CNS research to the next level. We are optimistic that these research initiatives will help define superior data collection and assessment methodologies in such disease areas as psychiatry, neurology and pain which are dependent upon subjective endpoints.”
The scientific leaders serving with Dr. Kalali on the Council are Peter Buckley, MD (Department of Psychiatry, Medical College of Georgia); Jeffrey Cummings, MD (David Geffen School of Medicine at UCLA); David Daniel, MD (United BioSource Corporation); John Greist, MD (Madison Institute of Medicine, University of Wisconsin and Healthcare Technology Systems); Philip Harvey, PhD (Emory University School of Medicine); Mark Rapaport, MD (David Geffen School of Medicine at UCLA, Cedars-Sinai Medical Center); and David Sheehan, MD (University of Southern Florida).
The need to establish concise methodologies for research initiatives within CNS studies is widely understood among researchers. Dr. Greist explained: “The subjective nature of clinician-rated and patient-reported outcomes is associated with relatively high error variance in measurement, as compared to objective, physiologic measures. This, in turn, may contribute to the high failure rate of clinical trials where reliance on non-physiologic endpoints for establishing efficacy is used. By perfecting the precision of subjective measures, we hope to enhance statistical power and reduce sample size, while improving signal detection within clinical trials.”
The FIDQ will meet regularly to discuss new developments and plan future efforts. “Systematic development of reliable, valid and novel signal detection methodologies is paramount for the FIDQ. There is a great need for such an undertaking in clinical research,” said Dr. Daniel. “The commitment to the advancement of evidenced-based clinical trial methodologies is core to the FIDQ and I am excited to be part of such an impressive team.”
The Foundation for Improving Data Quality is located in Southeastern, PA. For more information, visit www.fidq.org <http://www.fidq.org/>.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
